Core Insights - Real Bio Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange (HKEX) for the third time, with China International Capital Corporation (CICC) as the sole sponsor [1] - The company was previously listed in August 2022 and February 2025, indicating ongoing efforts to secure a public listing [1] - Founded in 2012, Real Bio focuses on the innovative research and development of drugs targeting viral infections, tumors, and cardiovascular diseases [1] Product Pipeline - The company has developed a comprehensive drug portfolio, including five candidate drugs: - Core product Azvudine, conditionally approved in China for treating HIV and COVID-19, with ongoing development for monotherapy and four combination therapies targeting multiple cancers and HIV [1] - Core product CL-197, aimed at long-term treatment of HIV infections [1] - Core product Dositinib, used for treating non-small cell lung cancer [1] - ZSSW-136, targeting malignant tumors [1] - MTB-1806, focused on treating acute ischemic stroke [1]
新股消息 | 真实生物三次递表港交所
智通财经网·2025-11-09 10:42